University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

Aalto University scientists have created a laser-based treatment that uses gentle heat to stop the progression of dry macular ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular degeneration, ...

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...

The clinical trial enrolled 38 adults aged 60 and older who had advanced geographic atrophy, the late stage of macular ...

Myopia, or nearsightedness, is a common eye condition. More than 40% of Americans can't see clearly at a distance because their eye is longer than normal. Usually myopia doesn't cause any problems ...

FRESNO, Calif. (KFSN) -- Our eyes give us a clear view of the world. Over time, that vision can become blurry. "Macular degeneration is an acquired degeneration of the macula," says Dr. Neesurg Mehta.

Support local journalism. A digital subscription is incredibly affordable and makes you the most informed person around. Click here and subscribe today Many frightening thoughts may go through your ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, which is ...

Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its chief executive officer, Gregory D. Kunst, will present preclinical data highlighting the ...

In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...